Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASCO 2022 | Remaining questions on bone marrow assessment of minimal residual disease

Radhika Bansal • 4 Jun 2022
ASCO 2022
Multiple Myeloma

Radhika Bansal, MBBS, Mayo Clinic, Rochester, MN, discusses unanswered questions regarding bone marrow assessment of minimal residual disease (MRD). This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Radhika Bansal

Insights into real-world outpatient administration of axi-cel and brexu-cel in R/R NHL 1:11
Insights into real-world outpatient administration of axi-cel and brexu-cel in R/R NHL
Radhika Bansal • 14 Jun 2024
Outpatient management of CAR-T therapy in multiple myeloma and lymphoma 2:22
Outpatient management of CAR-T therapy in multiple myeloma and lymphoma
Radhika Bansal • 9 Dec 2023
Outpatient management of patients with multiple myeloma treated with bispecific antibodies 1:49
Outpatient management of patients with multiple myeloma treated with bispecific antibodies
Radhika Bansal • 9 Dec 2023
Prognostic tool to identify CAR-T outcomes in patients with aggressive lymphoma 2:00
Prognostic tool to identify CAR-T outcomes in patients with aggressive lymphoma
Radhika Bansal • 11 Dec 2022

Related Videos

The iMMunoPET trial: 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma 4:45
The iMMunoPET trial: 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma
Ola Landgren • 6 Dec 2025
Reasons for treatment discontinuation in multiple myeloma: insights from the PREAMBLE registry 1:29
Reasons for treatment discontinuation in multiple myeloma: insights from the PREAMBLE registry
Karthik Ramasamy • 7 Dec 2025
The hottest myeloma abstracts from ASH 2025: in vivo CAR-T and MajesTEC-3 2:33
The hottest myeloma abstracts from ASH 2025: in vivo CAR-T and MajesTEC-3
Faith Davies • 7 Dec 2025
Transforming patient outcomes in myeloma through real-time, SMS-based monitoring of symptoms & QoL 2:30
Transforming patient outcomes in myeloma through real-time, SMS-based monitoring of symptoms & QoL
James Berenson • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals